LEADER 01275nam--2200397---450 
001 990006003730203316
005 20240213125631.0
010   $a978-0-12-800282-7
035   $a000600373
035   $aUSA01000600373
035   $a(ALEPH)000600373USA01
035   $a000600373
100   $a20150203d2014----km-y0itay50------ba
101   $aeng
102   $aNL
105   $a||||||||001yy
200 1 $aPharmacology of the blood brain barrier$etargeting CNS disorders$fedited by Thomas P. Davis$gserial editor S. J. Enna$gmanaging editor Lynn Lecount
210   $aAmsterdam [etc.]$cElsevier$dcopyr. 2014
215   $aXVI, 495 p.$d24 cm
225 2 $aAdvances in pharmacology$v71
410  0$1001000609420$12001$aAdvances in pharmacology$v71
606   $aFarmacologia$2BNCF
606 0 $aFisiologia$xPreparati galenici$2BNCF
676   $a612.82
702  1$aDAVIS,$bThomas
702  1$aENNA,$bS. J.
702  1$aLECOUNT,$bLynn
801  0$aIT$bsalbc$gISBD
912   $a990006003730203316
951   $a615 AIP/71$b5840 Farm.$c615$d00330485
959   $aBK
969   $aFAR
979   $aPAOLA$b90$c20150203$lUSA01$h1240
979   $aPAOLA$b90$c20150203$lUSA01$h1243
996   $aPharmacology of the blood brain barrier$91078628
997   $aUNISA